Cresset appoints new Non-Executive Director

Cambridge, 20th May 2024 – Cresset, innovative provider of computational drug discovery and development solutions that accelerate research outcomes, have announced the appointment of Dale Curtis as Non-Executive Director.

Dale will focus on go-to-market strategy, complementing the Cresset commercial team and bringing his international expertise to further support Cresset’s global growth. He replaces David Newble who has been appointed Cresset Group Chairman.

Dale is based in the USA where he is CEO of Astrix Technology LLC, having joined in September 2015 as President, and promoted in December 2020. He has extensive experience in the life sciences sector, developing strategic accounts and leading commercial growth, having held other senior commercial roles at Xybion Corporation and Biovia.

Dale Curtis, Non-Executive Director, Cresset

Commenting on the appointment, Cresset CEO Dr Rob Scoffin, said "we are delighted to welcome Dale as Non-Executive Director. His extensive experience will be invaluable as we look continue with our ambitious growth plans."

Dale Curtis commented, "I am honored to join in this important role. I am looking forward to working with my board colleagues and the entire Cresset team to serve the life sciences community through the provision of world class people and technology, driving digital transformation and accelerating drug discovery."